Journal of Cardiac Failure
Volume 13, Issue 5 , Pages 331-339 , June 2007

Isosorbide Dinitrate and Hydralazine in a Fixed-Dose Combination Produces Further Regression of Left Ventricular Remodeling in a Well-Treated Black Population With Heart Failure: Results From A-HeFT

  • Jay N. Cohn, MD

      Affiliations

    • From the Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationReprint requests: Jay N. Cohn, MD, Professor of Medicine, Cardiovascular Division, MC 508, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455.
    • ,
  • S. William Tam, PhD

      Affiliations

    • NitroMed, Inc., Lexington, Massachusetts
    • ,
  • Inder S. Anand, MD

      Affiliations

    • From the Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Anne L. Taylor, MD

      Affiliations

    • From the Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Michael L. Sabolinski, MD

      Affiliations

    • NitroMed, Inc., Lexington, Massachusetts
    • ,
  • Manuel Worcel, MD

      Affiliations

    • NitroMed, Inc., Lexington, Massachusetts
    • ,
  • for the A-HeFT Investigators

Received 6 November 2006 ,Revised 1 March 2007 ,Accepted 5 March 2007.

References 

  1. Cohn JN, Ferrari R, Sharpe N on Behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. JACC. 2000;35:569–582
  2. Wong M, Johnson G, Shabetai R, Hughes V, Bhat G, Lopez B, et al. for the V-HeFT VA Cooperative Studies Group Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure: Veterans Affairs Cooperative Studies V-HeFT I and II. Circulation. 1993;87:VI-65–VI-70
  3. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, et al. for the V-HeFT VA Cooperative Studies Group Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993;87:VI-5–VI16
  4. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN for the V-HeFT VA Cooperative Studies Group. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation. 1993;87:VI-17–VI-23
  5. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. J Am Coll Cardiol. 2004;43:2022–2027
  6. Konstam MA, Rouseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of angiotensin converting enzyme inhibitor enalapril on the long-term progression of ventricular dysfunction in patients with heart failure. Circulation. 1992;85:431–438
  7. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. for the SOLVD Investigators Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation. 1995;91:2573–2581
  8. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. JACC. 1995;25:1154–1161
  9. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. for the MOCHA Investigators Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807–2816
  10. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970–975
  11. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med. 1986;314:1547–1552
  12. Carson P, Ziesche S, Johnson G, Cohn JN for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Cardiac Failure. 1999;5:178–187
  13. Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, et al. for the A-HeFT Investigators African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail. 2002;8:128–135
  14. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, et al. for the African-American Heart Failure Trial Investigators Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057
  15. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiography. 1989;2:358–367
  16. Lamas GA, Vaughan DE, Parisi AE, Pfeffer MA. Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acute myocardial infarction. Am J Cardiol. 1989;63:1167–1173
  17. Kono T, Sabbah HN, Stein PD, Brymer JF, Khaja F. Left ventricular shape as a determinant of functional mitral regurgitation in patients with severe heart failure secondary to either coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1991;68:355–359
  18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458
  19. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Chamber Quantification Writing Group. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography. J Am Soc Echocardiogr. 2005;18:1440–1463
  20. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386–391
  21. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202–209
  22. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al, on behalf of the African-American Heart Failure Trial Investigators. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation 2007;115:1747–53.
  23. Wong M, Johnson G, Shabetai R, Hughes V, Bhat G, Lopez B, et al. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure: Veterans affairs cooperative studies V-HeFT I and II. Circulation. 1993;87:VI-65–VI-70
  24. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al. Investigators for The Bucindolol Heart failure/cardiac transplantation: dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632–1642
  25. Colucci WS, Packer M, Bristow MR, Gilbert M, Cohn JN, Fowler MB, et al. for the US Carvedilol Heart Failure Study Group Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800–2806
  26. Australia/New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol in patients with congestive heart failure due to ischaemic heart disease: final results from the ANZ heart failure research collaborative trial. Lancet. 1997;349:212–218
  27. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Congestive heart failure/myocardial disease: carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:1499–1506
  28. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The Precise Trial. Circulation. 1996;94:2807–2816
  29. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. The RESOLVD Pilot Study. Circulation. 2000;101:378–384
  30. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441–1446
  31. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  32. Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, et al. Influence of blood pressure on the effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol. 2007;49:32–39
  33. Wong M, Staszewsky L, Volpi A, Latini R, Barlera S, Hoglund C. Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in Heart Failure Trial (Val-HeFT). J Am Soc Echocardiography. 2002;15:293–307
  34. Maisel A. B-type natriuretic peptide levels: a potential “white count” for congestive heart failure. J Card Fail. 2001;7:183–193
  35. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278–1283
  36. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002;106:2454–2458
  37. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, et al. for the Val-HeFT Investigators Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006;119:70;e23–30
  38. Haga SB, Ginsburg GS. Prescribing BiDil: is it black and white?. J Am Coll Cardiol. 2006;48:12–14
  39. Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. Chest. 1978;73:8–13
  40. Moncada S. Nitric oxide in the vasculature: physiology and pathophysiology. J N Y Acad Sci. 1997;811:60–67
  41. Münzel T, Kurz S, Rajagopalan S, Martin T, Berrington WR, Thompson JA, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. J Clin Invest. 1996;98:1465–1470
  42. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation. 1991;84:35–39
  43. Gogia H, Mehra A, Parikh S, Raman M, Uppal JA, Johnson JV, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575–1580
  44. Prabhu SD. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res. 2004;94:1155–1157
  45. Cohn JN. Vasodilator therapy for heart failure: the influence of impedance on left ventricular performance. Circulation. 1973;48:5–8
  46. Konstam MA, Udelson JE, Anand IS, Cohn JN. Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail. 2003;9:350–353

 All decisions regarding this manuscript were made by a guest editor.A-HeFT was supported by NitroMed. The fixed-dose combination of isosorbide dinitrate and hydralazine was provided as BiDil.All authors have received grant support from NitroMed, Inc (JNC, ISA, ALT), or are employees of NitroMed (MW, MLS, SWT). Dr. Cohn has a royalty relationship with NitroMed based on his patents of the drug combination.

PII: S1071-9164(07)00070-X

doi: 10.1016/j.cardfail.2007.03.001

Journal of Cardiac Failure
Volume 13, Issue 5 , Pages 331-339 , June 2007

Article Tools

* Image Usage & Resolution